CA2856076C - Muscarinic m1 receptor agonists - Google Patents
Muscarinic m1 receptor agonists Download PDFInfo
- Publication number
- CA2856076C CA2856076C CA2856076A CA2856076A CA2856076C CA 2856076 C CA2856076 C CA 2856076C CA 2856076 A CA2856076 A CA 2856076A CA 2856076 A CA2856076 A CA 2856076A CA 2856076 C CA2856076 C CA 2856076C
- Authority
- CA
- Canada
- Prior art keywords
- carboxylate
- ethyl
- azepane
- piperidin
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)(CC(CC1)N(CC2)C*(*)CC2(C)C2OC2N(C)**)CN1*(OC*)=O Chemical compound CC(*)(CC(CC1)N(CC2)C*(*)CC2(C)C2OC2N(C)**)CN1*(OC*)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161632813P | 2011-11-18 | 2011-11-18 | |
| US61/632,813 | 2011-11-18 | ||
| PCT/GB2012/052857 WO2013072705A1 (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2856076A1 CA2856076A1 (en) | 2013-05-23 |
| CA2856076C true CA2856076C (en) | 2020-02-25 |
Family
ID=47278335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856076A Active CA2856076C (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US9187451B2 (enExample) |
| EP (1) | EP2780015B1 (enExample) |
| JP (2) | JP6083818B2 (enExample) |
| CN (2) | CN104039321B (enExample) |
| AU (3) | AU2012338581B2 (enExample) |
| BR (1) | BR112014012056B1 (enExample) |
| CA (1) | CA2856076C (enExample) |
| DK (1) | DK2780015T3 (enExample) |
| ES (1) | ES2619829T3 (enExample) |
| GB (1) | GB2511685A (enExample) |
| HU (1) | HUE033114T2 (enExample) |
| IN (1) | IN2014KN01075A (enExample) |
| PL (1) | PL2780015T3 (enExample) |
| PT (1) | PT2780015T (enExample) |
| SG (1) | SG11201402405QA (enExample) |
| WO (1) | WO2013072705A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039321B (zh) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | 药物化合物 |
| DK2897948T3 (en) * | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
| EP3102568B1 (en) * | 2014-02-06 | 2018-06-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
| GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) * | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| CN108226319A (zh) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | 一种检测卡巴拉汀贴剂中光学异构体的方法 |
| TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
| JP6691928B2 (ja) * | 2018-02-07 | 2020-05-13 | 株式会社ジンズホールディングス | アイウエアセット及び信号処理ユニット |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN113121495A (zh) * | 2020-01-10 | 2021-07-16 | 深圳市九明药业有限公司 | 一种地氯雷他定的制备方法 |
| WO2025167860A1 (zh) * | 2024-02-06 | 2025-08-14 | 南京迈诺威医药科技有限公司 | 一种含有占诺美林或其盐的药物组合物 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
| JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
| EP0786997A4 (en) | 1994-10-27 | 1998-03-11 | Merck & Co Inc | MUSCARINE ANTAGONISTS |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| AU7478496A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
| US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| AU3632297A (en) | 1996-08-26 | 1998-03-19 | Pfizer Inc. | Spirocyclic dopamine receptor subtype ligands |
| WO1998057641A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| WO1999032489A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| AU2095099A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists |
| AU2307899A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| CZ286152B6 (cs) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparentní a semitransparentní difrakční prvky |
| US6294555B1 (en) * | 1998-04-28 | 2001-09-25 | Dainippon Pharmaceutical Co., Ltd. | 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| PT1175224E (pt) | 1999-05-04 | 2005-07-29 | Schering Corp | Terapeutica de combinacao contra hiv com interferao-alfa peguilado e um antagonista de ccr5 |
| CZ301161B6 (cs) | 1999-05-04 | 2009-11-18 | Schering Corporation | Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující |
| NZ518255A (en) | 1999-09-13 | 2004-11-26 | Boehringer Ingelheim Pharma | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| ES2223588T3 (es) | 1999-10-13 | 2005-03-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de imidazolidinona sustituidos. |
| US7163938B2 (en) * | 2000-11-28 | 2007-01-16 | Eli Lilly And Company | Substituted carboxamides |
| US7164024B2 (en) | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| NZ533566A (en) | 2001-12-28 | 2007-03-30 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| ATE454381T1 (de) * | 2002-03-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Benzofuranderivat |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| WO2004014853A1 (en) | 2002-07-31 | 2004-02-19 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| PT1551835E (pt) | 2002-09-30 | 2007-03-30 | Neurosearch As | Novos derivados de 1, 4-diazabicicloalcano, sua preparação e utilização |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| PL376925A1 (pl) | 2002-11-27 | 2006-01-09 | Incyte Corporation | Pochodne 3-aminopirolidyny jako modulatory receptorów chemokiny |
| JPWO2004069828A1 (ja) | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
| EP1647553A4 (en) * | 2003-07-17 | 2008-12-31 | Astellas Pharma Inc | 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF |
| US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| CN1946402A (zh) | 2004-02-05 | 2007-04-11 | 先灵公司 | 用作ccr3拮抗剂的哌啶衍生物 |
| KR100863854B1 (ko) | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ｃｃｒ5 수용체 조절제 |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| JP2008521821A (ja) | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| WO2006105035A2 (en) | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| WO2006137485A1 (ja) | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| JP2009521483A (ja) * | 2005-12-22 | 2009-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| AU2007221214A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| EP1987034B1 (en) | 2006-02-22 | 2011-07-20 | Vertex Pharmceuticals Incorporated | Spiro condensed piperidines as modulators of muscarinic receptors |
| AU2007284548A1 (en) | 2006-08-15 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| JP2010513357A (ja) | 2006-12-22 | 2010-04-30 | ノバルティス アーゲー | Ｄｐｐ−ｉｖ阻害剤としての１−アミノメチル−１−フェニル−シクロヘキサン誘導体 |
| WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| UY31672A1 (es) * | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| JP5564033B2 (ja) | 2008-03-27 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体 |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| DK2379525T3 (en) * | 2008-12-19 | 2015-10-19 | Boehringer Ingelheim Int | Cyclic pyrimidin-4-carboxamides, as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD |
| NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2011112825A2 (en) | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| JP2013525370A (ja) | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| EP2563127A4 (en) | 2010-04-27 | 2013-11-06 | Merck Sharp & Dohme | PROLYLCARBOXYPEPTIDASE INHIBITORS |
| WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| EP2576520A1 (en) | 2010-05-28 | 2013-04-10 | GE Healthcare UK Limited | Radiolabeled compounds and methods thereof |
| BR112013006344A2 (pt) | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| CN104039321B (zh) | 2011-11-18 | 2017-02-22 | 赫普泰雅治疗有限公司 | 药物化合物 |
| DK2897948T3 (en) | 2012-09-18 | 2016-12-05 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS |
| CN105189482A (zh) | 2013-02-07 | 2015-12-23 | 武田药品工业株式会社 | 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯 |
| EP3102568B1 (en) | 2014-02-06 | 2018-06-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PL3265459T3 (pl) | 2015-02-13 | 2019-09-30 | Suven Life Sciences Limited | Związki amidowe jako agoniści receptora 5-HT4 |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
| GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201922758A (zh) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | 烯胺及烯胺的非鏡像選擇性還原 |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2012
- 2012-11-16 CN CN201280066372.3A patent/CN104039321B/zh active Active
- 2012-11-16 SG SG11201402405QA patent/SG11201402405QA/en unknown
- 2012-11-16 BR BR112014012056-0A patent/BR112014012056B1/pt active IP Right Grant
- 2012-11-16 JP JP2014541757A patent/JP6083818B2/ja active Active
- 2012-11-16 CA CA2856076A patent/CA2856076C/en active Active
- 2012-11-16 EP EP12794751.3A patent/EP2780015B1/en active Active
- 2012-11-16 HU HUE12794751A patent/HUE033114T2/en unknown
- 2012-11-16 US US14/358,984 patent/US9187451B2/en active Active
- 2012-11-16 PT PT127947513T patent/PT2780015T/pt unknown
- 2012-11-16 AU AU2012338581A patent/AU2012338581B2/en active Active
- 2012-11-16 CN CN201710078042.0A patent/CN106831541B/zh active Active
- 2012-11-16 PL PL12794751T patent/PL2780015T3/pl unknown
- 2012-11-16 IN IN1075KON2014 patent/IN2014KN01075A/en unknown
- 2012-11-16 WO PCT/GB2012/052857 patent/WO2013072705A1/en not_active Ceased
- 2012-11-16 ES ES12794751.3T patent/ES2619829T3/es active Active
- 2012-11-16 GB GB1410398.0A patent/GB2511685A/en not_active Withdrawn
- 2012-11-16 DK DK12794751.3T patent/DK2780015T3/en active
-
2015
- 2015-11-13 US US14/941,328 patent/US9573929B2/en active Active
-
2017
- 2017-01-19 JP JP2017007283A patent/JP6404374B2/ja active Active
- 2017-02-17 US US15/436,224 patent/US9907805B2/en active Active
- 2017-03-06 AU AU2017201505A patent/AU2017201505B2/en active Active
-
2018
- 2018-02-01 US US15/886,249 patent/US10413553B2/en active Active
- 2018-09-28 AU AU2018236871A patent/AU2018236871B2/en active Active
-
2019
- 2019-09-04 US US16/560,529 patent/US10973832B2/en active Active
-
2021
- 2021-04-09 US US17/226,523 patent/US11793817B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11793817B2 (en) | Muscarinic M1 receptor agonists | |
| US11091456B2 (en) | Muscarinic agonists | |
| EP3370828B1 (en) | Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| CA2994203C (en) | Azaspiro compounds as muscarinic agonists | |
| HK1201737B (en) | Muscarinic m1 receptor agonists | |
| HK1234408A (en) | Muscarinic m1 receptor agonists | |
| HK1234408A1 (en) | Muscarinic m1 receptor agonists | |
| HK1234408B (zh) | 毒蕈碱性m1受体激动剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171103 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20240911 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241203 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250613 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |